The Relationship between Atherogenic Index of Plasma and Obesity among Adults in Taiwan
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Data Collection
2.3. Definition of AIP and Obesity
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019, 15, 288–298. [Google Scholar] [CrossRef] [PubMed]
- Bays, H.E.; González-Campoy, J.M.; Bray, G.A.; Kitabchi, A.E.; Bergman, D.A.; Schorr, A.B.; Rodbard, H.W.; Henry, R.R. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther. 2008, 6, 343–368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bays, H.; Mandarino, L.; DeFronzo, R.A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 2004, 89, 463–478. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bays, H.E.; Toth, P.P.; Kris-Etherton, P.M.; Abate, N.; Aronne, L.J.; Brown, W.V.; Gonzalez-Campoy, J.M.; Jones, S.R.; Kumar, R.; La Forge, R.; et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J. Clin. Lipidol. 2013, 7, 304–383. [Google Scholar] [CrossRef] [Green Version]
- Zhu, X.; Yu, L.; Zhou, H.; Ma, Q.; Zhou, X.; Lei, T.; Hu, J.; Xu, W.; Yi, N.; Lei, S. Atherogenic index of plasma is a novel and better biomarker associated with obesity: A population-based cross-sectional study in China. Lipids Health Dis. 2018, 17, 37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeh, T.-L.; Chen, H.-H.; Chiu, H.-H.; Chiu, Y.-H.; Hwang, L.-C.; Wu, S.-L. Morbidity associated with overweight and obesity in health personnel: A 10-year retrospective of hospital-based cohort study in Taiwan. Diabetes Metab. Syndr. Obes. 2019, 12, 267–274. [Google Scholar] [CrossRef] [Green Version]
- Yeh, W.-C.; Chuang, H.-H.; Lu, M.-C.; Tzeng, I.S.; Chen, J.-Y. Prevalence of metabolic syndrome among employees of a taiwanese hospital varies according to profession. Medicine 2018, 97, e11664. [Google Scholar] [CrossRef]
- Dobiásová, M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: Theoretical and practical implications. Clin. Chem. 2004, 50, 1113–1115. [Google Scholar] [CrossRef]
- Dobiásová, M. [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: From research to practice]. Vnitr. Lek. 2006, 52, 64–71. [Google Scholar]
- Frohlich, J.; Dobiásová, M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin. Chem. 2003, 49, 1873–1880. [Google Scholar] [CrossRef]
- Niroumand, S.; Khajedaluee, M.; Khadem-Rezaiyan, M.; Abrishami, M.; Juya, M.; Khodaee, G.; Dadgarmoghaddam, M. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med. J. Islamic Repub. Iran 2015, 29, 240. [Google Scholar]
- Zhang, X.; Zhang, X.; Li, X.; Feng, J.; Chen, X. Association of metabolic syndrome with atherogenic index of plasma in an urban Chinese population: A 15-year prospective study. Nutr. Metab. Cardiovasc. Dis. 2019, 29, 1214–1219. [Google Scholar] [CrossRef] [PubMed]
- McLaughlin, T.; Abbasi, F.; Cheal, K.; Chu, J.; Lamendola, C.; Reaven, G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 2003, 139, 802–809. [Google Scholar] [CrossRef]
- McLaughlin, T.; Reaven, G.; Abbasi, F.; Lamendola, C.; Saad, M.; Waters, D.; Simon, J.; Krauss, R.M. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am. J. Cardiol. 2005, 96, 399–404. [Google Scholar] [CrossRef] [PubMed]
- Wong, N.D.; Wilson, P.W.; Kannel, W.B. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study. Ann. Intern. Med. 1991, 115, 687–693. [Google Scholar] [CrossRef] [PubMed]
- Kannel, W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am. J. Cardiol. 1995, 76, 69c–77c. [Google Scholar] [CrossRef]
- Dobiášová, M.; Frohlich, J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin. Biochem. 2001, 34, 583–588. [Google Scholar] [CrossRef]
- Dobiásová, M.; Frohlich, J. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: Changes during lipanor therapy]. Vnitr. Lek. 2000, 46, 152–156. [Google Scholar]
- Ivanova, E.A.; Myasoedova, V.A.; Melnichenko, A.A.; Grechko, A.V.; Orekhov, A.N. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Med. Cell. Longev. 2017, 2017, 1273042. [Google Scholar] [CrossRef] [Green Version]
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106, 3143–3421. [CrossRef]
- Ohta, T.; Saku, K.; Takata, K.; Nagata, N.; Maung, K.K.; Matsuda, I. Fractional esterification rate of cholesterol in high density lipoprotein (HDL) can predict the particle size of low density lipoprotein and HDL in patients with coronary heart disease. Atherosclerosis 1997, 135, 205–212. [Google Scholar] [CrossRef]
- Liu, J.; Yang, R.; Zhou, M.; Mao, W.; Li, H.; Zhao, H.; Wang, S.; Chen, W.; Dong, J.; He, Q. Fractional esterification rate of cholesterol in high-density lipoprotein associates with risk of coronary heart disease. Lipids Health Dis. 2017, 16, 162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fernández-Macías, J.C.; Ochoa-Martínez, A.C.; Varela-Silva, J.A.; Pérez-Maldonado, I.N. Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses. Arch. Med. Res. 2019, 50, 285–294. [Google Scholar] [CrossRef] [PubMed]
- Böger, R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res. 2003, 59, 824–833. [Google Scholar] [CrossRef] [Green Version]
- Dou, H.-X.; Wang, T.; Su, H.-X.; Gao, D.-D.; Xu, Y.-C.; Li, Y.-X.; Wang, H.-Y. Exogenous FABP4 interferes with differentiation, promotes lipolysis and inflammation in adipocytes. Endocrine 2020, 67, 587–596. [Google Scholar] [CrossRef]
- Lee, C.H.; Lam, K.S. Obesity-induced insulin resistance and macrophage infiltration of the adipose tissue: A vicious cycle. J. Diabetes Investig. 2019, 10, 29–31. [Google Scholar] [CrossRef]
- Lee, C.-H.; Lui, D.T.W.; Lam, K.S.L. Adipocyte Fatty Acid-Binding Protein, Cardiovascular Diseases and Mortality. Front. Immunol. 2021, 12, 589206. [Google Scholar] [CrossRef]
- Song, P.; Xu, L.; Xu, J.; Zhang, H.Q.; Yu, C.X.; Guan, Q.B.; Zhao, M.; Zhang, X. Atherogenic Index of Plasma is Associated with Body Fat Level in Type 2 Diabetes Mellitus Patients. Curr. Vasc. Pharm. 2018, 16, 589–595. [Google Scholar] [CrossRef]
Variables | Total | Non-Obesity (BMI < 27) | Obesity (BMI ≥ 27) | p Value |
---|---|---|---|---|
(n = 1312) | (n = 989) | (n = 323) | ||
Age (year) | 42.39 ± 8.90 | 42.20 ± 9.03 | 42.97 ± 8.47 | 0.18 |
SBP (mmHg) | 123.06 ± 16.09 | 120.01 ± 14.97 | 132.39 ± 15.83 | <0.001 |
DBP (mmHg) | 76.38 ± 12.39 | 74.09 ± 11.53 | 83.39 ± 12.31 | <0.001 |
BMI (kg/m2) | 24.50 ± 4.11 | 22.66 ± 2.46 | 30.13 ± 2.85 | <0.001 |
WC (cm) | 81.01 ± 10.55 | 76.97 ± 7.70 | 93.38 ± 8.22 | <0.001 |
ALT (U/L) | 25.74 ± 21.99 | 21.86 ± 17.52 | 37.63 ± 28.95 | <0.001 |
FPG (mg/dL) | 90.36 ± 18.84 | 88.13 ± 13.73 | 97.20 ± 28.37 | <0.001 |
HDL-C (mg/dL) | 55.73 ± 13.28 | 58.13 ± 13.05 | 48.37 ± 11.10 | <0.001 |
LDL-C (mg/dL) | 116.02 ± 29.33 | 113.29 ± 28.52 | 124.29 ± 30.22 | <0.001 |
TC (mg/dL) | 190.68 ± 32.46 | 189.57 ± 31.73 | 194.07 ± 34.45 | 0.03 |
TG (mg/dL) | 99.19 ± 70.37 | 88.32 ± 61.06 | 132.46 ± 85.14 | <0.001 |
Men, n (%) | 501 (38.19%) | 341 (34.48%) | 160 (49.54%) | <0.001 |
HTN, n (%) | 293 (22.33%) | 149 (15.07%) | 144 (44.58%) | <0.001 |
DM, n (%) | 62 (4.73%) | 32 (3.24%) | 30 (9.29%) | <0.001 |
Hyperlipidemia, n (%) | 603 (45.96%) | 411 (41.56%) | 192 (59.44%) | <0.001 |
Metabolic syndrome, n (%) | 223 (17.00%) | 59 (5.97%) | 164 (50.77%) | <0.001 |
Variables | AIP | ||||
---|---|---|---|---|---|
Total | Low (<−0.3387) | Middle (−0.3387, −0.059) | High (>−0.059) | p Value | |
(n = 1312) | (n = 437) | (n = 438) | (n = 437) | ||
Age (year) | 42.39 ± 8.90 | 39.84 ± 8.38 | 42.79 ± 8.72 a | 44.53 ± 8.98 a,b | <0.001 |
SBP (mmHg) | 123.06 ± 16.09 | 116.59 ± 14.61 | 122.52 ± 15.66 a | 130.08 ± 15.08 a,b | <0.001 |
DBP (mmHg) | 76.38 ± 12.39 | 71.06 ± 10.55 | 75.48 ± 11.69 a | 82.61 ± 12.04 a,b | <0.001 |
BMI (kg/m2) | 24.50 ± 4.11 | 22.30 ± 3.30 | 24.39 ± 3.91 a | 26.81 ± 3.80 a,b | <0.001 |
WC (cm) | 81.01 ± 10.55 | 74.36 ± 7.81 | 80.58 ± 9.49 a | 88.08 ± 9.42 a,b | <0.001 |
ALT (U/L) | 25.74 ± 21.99 | 17.64 ± 9.65 | 23.52 ± 16.27 a | 36.08 ± 30.29 a,b | <0.001 |
FPG (mg/dL) | 90.36 ± 18.84 | 85.63 ± 10.98 | 88.84 ± 11.86 a | 96.61 ± 27.25 a,b | <0.001 |
HDL-C (mg/dL) | 55.73 ± 13.28 | 67.08 ± 11.30 | 55.55 ± 9.21 a | 44.56 ± 7.95 a,b | <0.001 |
LDL-C (mg/dL) | 116.02 ± 29.33 | 103.06 ± 24.47 | 117.09 ± 26.24 a | 127.75 ± 31.47 a,b | <0.001 |
TC (mg/dL) | 190.68 ± 32.46 | 184.81 ± 30.75 | 188.63 ± 30.11 | 198.59 ± 34.82 a,b | <0.001 |
TG (mg/dL) | 99.19 ± 70.37 | 49.33 ± 12.05 | 81.05 ± 16.10 a | 167.22 ± 83.82 a,b | <0.001 |
Men, n (%) | 501 (38.19%) | 55 (12.59%) | 162 (36.99%) a | 284 (64.99%) a,b | <0.001 |
HTN, n (%) | 293 (22.33%) | 37 (8.47%) | 79 (18.04%) a | 177 (40.50%) a,b | <0.001 |
DM, n (%) | 62 (4.73%) | 8 (1.83%) | 12 (2.74%) | 42 (9.61%) a,b | <0.001 |
Hyperlipidemia, n (%) | 603 (45.96%) | 134 (30.66%) | 165 (37.67%) | 304 (69.57%) a,b | <0.001 |
Metabolic syndrome, n (%) | 223 (17.00%) | 5 (1.14%) | 29 (6.62%) a | 189 (43.25%) a,b | <0.001 |
Variables | Unadjusted OR | (95% CI) | p Value | Adjusted OR | (95% CI) | p Value |
---|---|---|---|---|---|---|
Age (year) | 1.01 | (0.996–1.02) | 0.18 | 0.97 | (0.96–0.99) | 0.005 |
Sex (men versus women) | 1.87 | (1.45–2.41) | <0.001 | 0.54 | (0.38–0.76) | <0.001 |
HTN (yes versus no) | 4.54 | (3.43–6.00) | <0.001 | 3.74 | (2.65–5.30) | <0.001 |
DM (yes versus no) | 3.06 | (1.83–5.12) | <0.001 | 1.85 | (0.99–3.49) | 0.06 |
HDL-C (mg/dL) | 0.93 | (0.92–0.94) | <0.001 | 1.00 | (0.97–1.03) | 0.97 |
TC (mg/dL) | 1.00 | (1.00–1.01) | 0.03 | 0.96 | (0.94–0.99) | 0.002 |
TG (mg/dL) | 1.01 | (1.007–1.01) | <0.001 | 1.01 | (1.00–1.01) | 0.005 |
LDL-C (mg/dL) | 1.01 | (1.01–1.02) | <0.001 | 1.05 | (1.02–1.07) | <0.001 |
AIP | ||||||
Low | 1.00 | - | - | - | - | - |
Middle | 3.79 | (2.48–5.79) | <0.001 | 2.31 | (1.41–3.78) | 0.001 |
High | 9.74 | (6.49–14.62) | <0.001 | 3.22 | (1.71–6.07) | <0.001 |
Variables | AUC (95% CI) | p Value | Cut-Off Point | Sensitivity | Specificity |
---|---|---|---|---|---|
TC (mg/dL) | 0.53 (0.50–0.57) | 0.07 | 200.50 | 0.41 | 0.66 |
TG (mg/dL) | 0.71 (0.68–0.74) | <0.001 | 82.50 | 0.75 | 0.60 |
LDL-C (mg/dL) | 0.61 (0.57–0.64) | <0.001 | 116.50 | 0.58 | 0.58 |
AIP | 0.74 (0.70–0.77) | <0.001 | −0.16 | 0.74 | 0.63 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhang, J.-S.; Yeh, W.-C.; Tsai, Y.-W.; Chen, J.-Y. The Relationship between Atherogenic Index of Plasma and Obesity among Adults in Taiwan. Int. J. Environ. Res. Public Health 2022, 19, 14864. https://doi.org/10.3390/ijerph192214864
Zhang J-S, Yeh W-C, Tsai Y-W, Chen J-Y. The Relationship between Atherogenic Index of Plasma and Obesity among Adults in Taiwan. International Journal of Environmental Research and Public Health. 2022; 19(22):14864. https://doi.org/10.3390/ijerph192214864
Chicago/Turabian StyleZhang, Jen-Shan, Wei-Chung Yeh, Yi-Wen Tsai, and Jau-Yuan Chen. 2022. "The Relationship between Atherogenic Index of Plasma and Obesity among Adults in Taiwan" International Journal of Environmental Research and Public Health 19, no. 22: 14864. https://doi.org/10.3390/ijerph192214864